Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) (ADAPT)

Clinical Trial ID NCT01582672

PubWeight™ 30.61^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01582672

Top papers